Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: lipid vector cancer therapeutics - Aqualis

Drug Profile

Research programme: lipid vector cancer therapeutics - Aqualis

Alternative Names: CP-4200

Latest Information Update: 07 Nov 2013

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Clavis Pharma; Mount Sinai School of Medicine
  • Developer Aqualis; Icahn School of Medicine at Mount Sinai
  • Class Aza compounds; Oleic acids; Pyrimidine nucleosides; Ribonucleosides
  • Mechanism of Action DNA methylation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Haematological malignancies; Solid tumours

Most Recent Events

  • 07 Nov 2013 Research programme: lipid vector cancer therapeutics - Aqualis is available for licensing as of 07 Nov 2013. http://aqualis.no/
  • 09 Oct 2013 Clavis Pharma is now called Aqualis
  • 29 Aug 2013 Discontinued - Preclinical for Haematological malignancies in Norway (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top